GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Qrons Inc (OTCPK:QRON) » Definitions » Investments And Advances

Qrons (QRON) Investments And Advances : $0.00 Mil (As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Qrons Investments And Advances?

Qrons's Investments And Advances for the quarter that ended in Mar. 2024 was $0.00 Mil.


Qrons Investments And Advances Historical Data

The historical data trend for Qrons's Investments And Advances can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Qrons Investments And Advances Chart

Qrons Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Investments And Advances
Get a 7-Day Free Trial - - - - -

Qrons Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Investments And Advances Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Qrons Investments And Advances Calculation

Investments And Advances includes all the non-current investments in affiliates, real estate, securities, etc.


Qrons (QRON) Business Description

Traded in Other Exchanges
N/A
Address
28-10 Jackson Avenue, No. 26N, Long Island City, New York, NY, USA, 11101
Qrons Inc is a biotechnology company developing advanced cell-based solutions to combat neuronal injuries with a laser focus on traumatic brain injuries. The technology would treat a wide range of neurodegenerative diseases. The treatment integrates proprietary, engineered mesenchymal stem cells, 3D printable scaffolding, smart materials, and a novel delivery system. The firm has two product candidates, QS100TM for treating penetrating brain injuries and QS200TM, for treating concussions and other diffused axonal injuries.
Executives
John N Bonfiglio officer: Chief Operating Officer C/O MICROLIN BIO, INC., NEW YORK NY 10022
Jonah Meer director, 10 percent owner, officer: CEO, CFO and Secretary 28-10 JACKSON AVENUE, #26N, LONG ISLAND CITY NY 11101
Ido Merfeld director, 10 percent owner, officer: President 153 HAGILBOA STREET, NIRIT L3 44805